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Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than
in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in
females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic
nonadherence and suicide and pose significant problems in the long term management of women with
schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and
strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic
hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address
these significant side effects and help the field better personalize the treatment of women with schizophrenia.
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Hyperprolactinemia and related consequences are known
side effects of several first and second generation antipsy-
chotics. Elevation of serum prolactin by antipsychotic drug
and clinical manifestations associated with this condition
has been recognized for more than three decades [1].
Nevertheless, the syndrome of antipsychotic-induced hy-
perprolactinemia has been relatively neglected. A review
article in 2004 reported that from 1966–2004 a search of
the Medline database returned 1717 journal articles on an-
tipsychotics and extrapyramidal side effects, yet only 375
articles on antipsychotics and hyperprolactinemia [2].
Hallewell and colleagues [3] performed a survey and
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reproduction in any medium, provided the orunderestimate the prevalence of key symptoms associated
with hyperprolactinemia. A recent cohort study reported
that among 194 schizophrenia and bipolar patients receiv-
ing antipsychotics from a single community mental health
facility in the UK, 38% had prolactin levels above the
upper limit of normal, two thirds of whom had signifi-
cantly elevated levels with clinical consequences. Women
were particularly at risk for elevations and associated con-
sequences, with over 50% of women in the study having
abnormal prolactin levels [4]. In recent years this issue has
begun to gain more attention. The last iteration of the
Patient Outcomes Research Team (PORT) guidelines spe-
cifically addresses the issue of hyperprolactinemia associ-
ated with antipsychotic use however, too few randomized
double blind trials were available to make and evidence
based recommendation [5]. Also very recently, suicide risk
has been found to be significantly increased with symp-
tomatic hyperprolactinemia [6]. Our group has beend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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currently running an adjunct treatment trial to improve
outcomes in women with this distressing side effect. In
this manuscript, we review the physiology and treatment
of elevated prolactin secondary to antipsychotic medica-
tions and present the rationale and protocol for an on-
going clinical trial that addresses this issue in women.Prolactin physiology
The main physiologic function of prolactin is to cause
breast enlargement during pregnancy and milk production
during lactation. Prolactin is an amino acid polypeptide
hormone secreted by the lactotroph cells of the anterior
pituitary. In a pulsatile manner, this 199 amino acid hor-
mone is released with 13–14 peaks per day and an
interpulse interval of about 95 minutes. Prolactin levels
show a circadian rhythm, with a maximum level reached
about 4 hours after the onset of sleep and a minimum
level reached about 6 hours after waking [7]. Transient
and mild increases in prolactin levels occur in response to
sexual activity, stress and eating [8]. In women, prolactin
levels are typically higher during mid cycle and the second
half of the menstrual cycle. During pregnancy, serum pro-
lactin levels increase to reach levels 10–20 times the nor-
mal value. Prolactin elevations during and post pregnancy
can reach 200 ng/ml at full term and 300 ng/ml while
nursing [9]. Levels generally normalize approximately
3 weeks postpartum in the absence of nursing. The reduc-
tions in sexual functioning and fertility associated with
nursing may have evolutionary advantages. In animals,
prolactin is known to have an important function in pro-
moting maternal behavior; however, this has not been
proven in humans. Because women have a physiologic
purpose for prolactin elevations, the female prolactin sys-
tem may be more likely to respond to stimuli, which may
underlie significantly higher prolactin levels in women ver-
sus men after dopamine antagonist treatment. Men are
more likely to have a buffer system in place to guard
against significant prolactin elevations.Normal prolactin levels
Despite these variations in serum prolactin levels, both
within and between individuals, there is a reasonable con-
sensus regarding the upper limit of the normal range.
Some authorities have suggested that the upper limit is
25 ng/ml in both men and women [10,11]. Others have
used >10 ng/ml in males and >20 in females [12] and yet
others have used >15-16 ng/ml in both sexes [13,14].
The most recent and more conservative reports suggest
that >18-20 ng/ml in men and >24 ng/ml in non-
pregnant, non-nursing women should be considered the
upper limits for prolactin serum concentrations [15-18].Prolactin control
Inhibition and stimulation
Prolactin secretion is under the control of various peptide
and steroid hormones and neurotransmitters [19]. Dopa-
mine, however, is the predominant prolactin-inhibiting
factor in humans and animals. In the tuberoinfundibular
neurons of the hypothalamus, dopamine is produced and
released from nerve endings. It is transported by the portal
hypophyseal circulation to the pituitary, where it binds to
dopamine D2 receptors on the membrane of the lactotroph
cells [20]. The presence of dopamine suppresses the release
of prolactin to a minimum. Dopamine D2 antagonists, such
as most antipsychotics, bind to the D2 receptors and lead
to the release of prolactin in the lactotroph cells. Animal
and human studies demonstrate that serotonin may stimu-
late prolactin secretion [21] as well as several peptide neu-
rotransmitters, including thyrotropin releasing hormone
and cholecystokinin [19]. These effects are not as well
characterized or robust as that of dopamine on prolactin
control.
Antipsychotic medications and prolactin
Virtually all antipsychotic drugs have the capacity to block
D2 receptors in the mesolimbic and mesocortical areas,
which is believed to be integral for efficacy of these agents.
In other areas of the brain, however, areas of D2 blockade
can cause significant adverse effects. Extrapyramidal side
effects such as Parkinsonism result from D2 antagonism
in the striatum, while blockade of D2 receptors on
lactotroph cells causes hyperprolactinemia, since the main
inhibitory influence (i.e., dopamine) is removed. Conven-
tional antipsychotics in people with schizophrenia as well
as healthy individuals cause prolactin elevations within
hours of taking these agents [22,23]. Studies with first gen-
eration antipsychotics (FGAs) (3–9 weeks) demonstrate
that therapeutic doses of any of these medications cause
prolactin elevations of up to 10 fold and elevations have
been reported to correlate to the dose [24]. The propensity
to elevate prolactin levels varies among second-generation
antipsychotics (SGAs). Clozapine has a low propensity to
block dopamine in the tuberinfundibular pathway and
has a negligible effect on plasma prolactin levels [25].
Olanzapine causes transient elevations in plasma prolactin
levels. During treatment in adults, prolactin levels remain
slightly elevated in about 1/3 of patients [26]. As with
FGAs, elevation of prolactin with olanzapine appears to be
a dose related phenomenon [27]. Mean prolactin levels
during 10–30 mg daily treatment with olanzapine are ap-
proximately 17 ng/ml, which is higher than that of nor-
mals, drug-free patients and clozapine-treated patients
[28]. Quetiapine has negligible effects on the elevation of
prolactin. In all of the large trials of quetiapine, prolactin
levels were reported to decrease from baseline to endpoint
during quetiapine treatment and no differences were noted
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though elevations may occur with ziprasidone. In a
double-blind study elevated prolactin levels were seen
in over 40% of patient treated with ziprasidone at the
end of 8 weeks as were over 60% in the olanzapine
treated group [33].
Of all the SGAs, risperidone and paliperidone [34] have
the highest propensity to elevate plasma prolactin levels,
and do so in a dose-related fashion. It is also well
established that, while high potency FGAs have prolactin
raising capabilities, risperidone and paliperidone elevate
prolactin significantly more than FGAs. In a naturalistic
cross sectional study in women, prevalence of elevated pro-
lactin (>24 ng/ml) was higher in those prescribed risperi-
done (88%) as compared to a conventional antipsychotic
(48%) [17]. Also, in a double blind 12 week randomized
trial by our group, prolactin levels were 50.6 ± 40.4 mg/dl,
24.4 ± 18.5 mg/dl, and 8.2 ± 4.4 mg/dl for risperidone,
fluphenazine and quetiapine, respectively (F = 7.5,df = 2,
p = 0.005, controlling for sex). The women in this study
treated with a fixed risperidone dose of 4 mg/day had
mean prolactin levels of 92 ng/ml after 12 weeks of treat-
ment on risperidone, an elevation with potential clinical
significance [35].
Aripiprazole treatment has been associated with signifi-
cant decreases in serum prolactin levels. In a recent double
blind randomized trial by Kane and colleagues [36] mean
prolactin levels decreased in the aripiprazole group from
33.4 ng/ml to 5.2 ng/ml in the 6 week trial, while prolactin
levels in the perphenazine group remained unchanged at
35.8 ng/ml to 35.5 ng/ml. Another recent 4 week double-
blind randomized trial reported that prolactin levels
were significantly decreased in the aripiprazole group
(−9.0 ng/ml) compared to a mean increase of 55.4 ng/
ml in the risperidone group. In this study, the percent-
age of schizophrenia patients who had an abnormal pro-
lactin levels (>25 ng/ml) at endpoint was significantly
higher in the risperidone group (93%) than in the
aripiprazole group (5%) [37]. The absence of significant
prolactin elevation with aripiprazole may be explained
by aripiprazole’s partial agonism at D2 receptors, in con-
trast to the D2 antagonism of other second-generation
agents. Aripiprazole has been shown to act as an agonist
in pituitary cells at the molecular level and thus,
lactotroph cells do not become blocked by aripiprazole
treatment [38].
Consequences of elevated prolactin
Methodological problems in the existing literature make it
difficult to determine the prevalence of symptomatic hy-
perprolactinemia in persons treated with antipsychotics.
Many previous studies have only examined prolactin levels
and not assessed its symptomatic consequences. Due to
inter-individual differences in responses to prolactin,elevated prolactin may at times be asymptomatic. Elevated
prolactin levels with no apparent consequences are more
common in males, as women tend to have menstrual
period abnormalities and other effects with significantly
elevated prolactin levels. Many studies in the past have
done a poor job at assessing presence of symptomatic side
effects in women. Additionally, cross sectional studies can
only show an association between symptoms and raised
prolactin; proving a causal relationship can be more com-
plex. Ideally, it requires a follow up design to determine
whether reversal of hyperprolactinemia is accompanied by
symptom resolution. Few studies have taken these issues
into account.
Health professionals often fail to detect antipsychotic
induced hyperprolactinemia symptoms [34]. There are
several reasons for this, including the nature of the
symptoms and the attitudes of both patients and health
professionals. Some patients may be embarrassed to dis-
cuss endocrine and sexual symptoms, and do not nor-
mally volunteer symptoms to the clinical or research
staff. Unlike some antipsychotic adverse effects (e.g.,
extrapyramidal symptoms and weight gain), some symp-
toms of hyperprolactinemia may not be not visibly stig-
matizing, which reduces their detection. Nonadherence
to antipsychotic treatment is common with prolactin re-
lated side effects and may be due to many of symptoms
discussed below. In a large nationwide survey in almost
900 people with schizophrenia taking antipsychotic med-
ications, almost 60% reported nonadherence, with pro-
lactin and endocrine related effects being one of the
commonly cited reasons, decreasing the odds of adher-
ence by about 30% [39].
a. Galactorrhea
Galactorrhea secondary to prolactin elevation is more
common in women than in men. Estimates of the preva-
lence of galactorrhea vary from 10-50%. A well-conducted
study found that 28/150 women (19%) developed galactor-
rhea within 75 days of commencing conventional anti-
psychotic treatment [40]. In this study, only 8 women
reported the symptom on their own to the clinician, illus-
trating that symptomatic hyperprolactinemia is often
unrecognized or under-reported. Lactation from the breast
in the nonpregnant state is most likely distressing to
women who suffer from a reality distortion illness and
likely also to interfere with social and intimate relationships
[41]. Gynecomastia also is common and can occur in both
men and women.
b. Menstrual abnormalities
Menstrual abnormalities are a frequently occurring side ef-
fect that often goes unnoticed and under recognized in
clinical trials. Typically, this information is not volunteered
and clinical investigators do not evaluate this side effect.
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irregularities in women with schizophrenia receiving long-
term treatment with conventional antipsychotics or risperi-
done. In these studies the reported prevalences were 25%,
26%, 40%, 45%, 55%, 56% and 78% [12,24,42-46]. While
these studies had small sample sizes and no clear definition
of oligomenorrhea or amenorrhea, it is still evident that
many women may experience these side effects. In a cross
sectional study of 42 women prescribed risperidone, 48%
experienced abnormal menstrual cycles. In our previous
12-week double blind pilot trial, 100% of female subjects in
the risperidone group experienced amenorrhea during
treatment [35]. Women who experience amenorrhea or
oligomenorrhea are likely infertile or subfertile. Long-term
amenorrhea also increases the risk of bone mineral density
loss and cardiovascular disease [47].
c. Sexual dysfunction
Sexual dysfunction has been implicated as one of the
major factors contributing to noncompliance with anti-
psychotic medications [48-51]. A survey identified “per-
sonal relationships” as one of the treatment areas with the
most unmet needs noted by people with schizophrenia
[52]. Quality of life may be improved with better hormonal
and sexual functioning as well [53,54]. It can be hypothe-
sized that a better focus on sexuality and preventing sexual
dysfunction in schizophrenia would be a major benefit for
improving treatment compliance and life quality.
While sexual dysfunction and diminished sexual func-
tioning during antipsychotic treatment also may be
caused by sedation, weight gain, extrapyramidal side ef-
fects, tardive dyskinesia, cholinergic antagonism, alpha-
adrenergic blockade and calcium channel blockade
[55-58], the evidence that elevated prolactin contributes
to sexual dysfunction is convincing. Hyperprolactinemia
is known to cause hypogonadism and decrease testoster-
one levels [59]. Prolactin itself appears to have a direct
effect on sexual activity as normalization of prolactin
levels with bromocriptine has been shown to restore
sexual functioning before testosterone levels increase
[39]. In non-psychiatric subjects, Faiman [60] stated that
80% of men with serum prolactin levels >50 ng/ml
complained of impaired libido and impotence. Ghadirian
et al. [45] found that elevated serum prolactin correlated
with worse sexual dysfunction in men. Similar results
were reported by Burke et al. in the mid 1990s [61].
Other studies have had variable results for correlational
type analyses but most generally report higher rates of
sexual dysfunction and menstrual disturbances with
higher prolactin levels [62-65].
The psychiatric literature contains several reports de-
scribing sexual disturbances in schizophrenia, but very
few well-designed studies address this issue. Few reports
describe sexual function or dysfunction in women. Thedefinition and measurement of sexual dysfunction has
been inconsistent, but a few general classifications ap-
pear in the existing literature [66]. In men, it appears
that the most commonly reported (30-60%) sexual side
effects associated with traditional antipsychotics are erec-
tion and ejaculation disturbances [67]. Difficulty achieving
and maintaining erection is a common complaint as is de-
layed or inhibited ejaculation, retrograde and spontaneous
ejaculation. Diminished libido and decreased orgasm qual-
ity are also commonly reported in men. Priapism, a
sustained painful erection that can result in permanent
impotence, has also been reported [68,69]. Women report
decreased libido and orgasmic dysfunction, including diffi-
culty achieving orgasm, changes in the quality of orgasm
and anorgasmia [40,59]. Women may also experience
dysparenuria secondary to vaginal atrophy and dryness.
Sexual dysfunction appears to be a particularly salient
issue in women treated with antipsychotic medications:
Howes et al. [14] found an odds ratio (OR) of 15.2 for
risk of sexual dysfunction in women with schizophrenia
compared to normal controls, compared to an OR 3.7 in
men. Recent reports suggest 59% [70] to 80% [71] of
women with schizophrenia experience sexual dysfunc-
tion, particularly those treated with conventional anti-
psychotics or risperidone.
d. Other adverse effects
Bone mineral density Osteoporosis is a systemic skel-
etal disease characterized by low bone mass and mic-
roarchitectural deterioration of bone tissue, with a
consequent increase in bone fragility and susceptibility
to fracture. People with schizophrenia represent a high-
risk group for developing osteoporosis because of the
disease itself, long-term antipsychotic drug treatment,
lack of exercise, poor nutrition and high rates of smok-
ing [72,73]. Hyperprolactinemia is known to increase
the risk of bone mineral density (BMD) loss in patients
with schizophrenia with long term antipsychotic drug
treatment, either through secondary hypogonadism [74]
or hyperprolactinemia itself [75]. Previous studies have
demonstrated that between 32-65% of patients treated
with antipsychotic drugs suffer from bone mineral loss,
leading to osteoporosis [74,76]. Bone fractures occur
more frequently in people with schizophrenia taking anti-
psychotics than in the nonpsychiatric population [77,78].
In a recent study by our group in Asian patients with
schizophrenia, 18/21 (86%) of women with schizophrenia
treated with haloperidol had significant bone mineral
density loss as compared to 9/23 (39%) of women in the
normal control group [15]. Other recent evidence suggests
that having amenorrhea or using prolactin elevating anti-
psychotic drugs are associated with a higher risk for osteo-
porosis and fracture [79-82]. Very recently, Graham and
others [83] published a literature review showing that first
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agents such as risperidone show high prolactin elevations
and are associated with an increased risk of osteoporosis
and fracture.
Pituitary tumors Lactotroph cells normally occupy 10-
15% of the pituitary gland. Knocking out the Dc receptor
in mice results in a striking progressive increase in
lactotroph cells in the pituitary gland and the rate of pitu-
itary tumors [84]. In these same mice, prolactin levels are
6 times higher in females as compared to males and fe-
males develop tumors much earlier than males. Long term
treatment with antipsychotics in mice have led to the de-
velopment of pituitary adenomas and adenocarcinomas
[85]. Recent pharmacovigilance studies in humans have
found through the FDA’s Adverse Event Reporting System
that a significantly greater proportion of pituitary tumors
were reported with risperidone than with other available
antipsychotics [85,86]. Another prospective study found
that pituitary volume significantly increases over one year
in people treated with prolactin elevating antipsychotics
[87]. The true risk of pituitary tumor with prolactin elevat-
ing medications remains unclear. Among the few studies
that have addressed whether dopamine receptor antago-
nists increase risk of breast cancer, results have been
conflicting [88]. However, until more data is available, it
remains of concern with long term use.
Suicide A major impetus for this review and presentation
of our clinical trial protocol was a BMC Psychiatry paper
published in June of 2012 that examined risk factors for
suicidal behaviors in a large 3 year multinational study
(SOHO study) with over 8,000 adult patients with schizo-
phrenia. This was the first study to examine prolactin re-
lated effects as a risk factor of suicide. The authors report
that prolactin related effects were profoundly associated
with increased suicide risk: amenorrhea increased the sui-
cide risk by 64%, galactorrhea by 163% and gynecomastia
by 200%. They also found that 84% of the patients with
prolactin related adverse effects were female [6]. The exact
mechanism for the suicide risk increase is unclear. Poten-
tial causes include nonadherence to treatment, low quality
of life associated with sexual dysfunction or increased
rates of depression and anxiety associated with prolactin
elevation effects [89-91]. Nonetheless, our increasing
knowledge of significant prolactin related side effects and
this new data on very large relative increases in risks of
suicidality associated with these side effects mandate in-
creased attention to prolactin-mediated adverse effects of
antipsychotic treatments and a search for effective treat-
ments for antipsychotic-induced hyperprolactinemia, par-
ticularly in women.
Our group has been working on identification [18], ef-
fective rating [35,57,92], consequences [15,35], recognition[57,68,93] and effective treatment [35,94] of prolactin-
associated side effects for over 13 years. We have identi-
fied what we think to be the most effective strategy for
managing these effects in women and are now running an
NIMH funded R01 double blind, placebo controlled ran-
domized clinical trial to address high prolactin levels with
associated symptoms in women with schizophrenia, the
DAAMSEL study (Dopamine Partial Agonist, Aripiprazole,
for the Management of Symptomatic ELevated Prolactin) It
is a 4 year study with a target enrollment of 50 women with
schizophrenia treated with risperidone, paliperidone or
FGAs and with elevated prolactin and sexual side effects
(menstrual abnormalities or galactorrhea) at baseline.
Participants will be followed for 16 weeks on adjunct
aripiprazole or placebo. Outcome measures include
resolution of menstrual abnormalities or galactorrhea,
improvement in sexual functioning, prolactin level im-
provement, changes in bone resorption measures, psy-
chiatric symptoms, quality of life and related metabolic
effects. We are pleased to bring attention to our on-
going study and to publish protocol details as ongoing
attention to clinical trials will help improve recognition
and reporting of side effects related to antipsychotic-
induced prolactin elevations as well as impact on study
recruitment (NCT#01338298). Below is the rationale
for why we use low dose aripiprazole and a summary of
the study methodology.
Treatment rationale
Few evidence-based treatment options are available for
hyperprolactinemia and associated side effects in pa-
tients who are treated with a potent D2 blocking drug. A
reduction in dose in the offending antipsychotic is the
simplest treatment strategy, but its effectiveness is ques-
tionable and it carries the risk or precipitating an exacer-
bation or relapse of psychotic symptoms.
Switching to a prolactin sparing antipsychotic may be
effective for decreasing prolactin [16,95-100]. However,
these studies provide insufficient evidence to examine
the effects of switching on symptom changes and relapse
rates or on symptomatic improvement of prolactin re-
lated side effects and the risk of relapse is present
[95,101]. Lee et al. [96] reported that while all patients
switched from risperidone to aripiprazole have amelior-
ation of symptomatic hyperprolactinemia, 29% of the pa-
tients experienced aggravated auditory hallucinations.
We also have pilot data in 40 women previously psychi-
atric stable on risperidone but switched to aripiprazole
due to prolactin-related symptoms; of these 40% (16/40)
had exacerbations in psychotic symptoms. Kuloglu et al.
[102] did have 5 women switch successfully, however, the
team warn against the accumulating literature suggesting
increases in psychotic symptoms during and after a taper
or switch to aripiprazole monotherapy. Clinicians do not
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monotherapy with aripiprazole compared to risperidone,
as evidenced by the smaller market share of aripiprazole
relative to other first line antipsychotics. No data are avail-
able from large-scale non-industry sponsored clinical trials
comparing the efficacy of aripiprazole to the efficacy with
risperidone or other second generation antipsychotics.
Observational studies have reported greater effectiveness
for symptom improvement with olanzapine and risperi-
done than with aripiprazole [103,104].
Other pharmacologic treatments for prolactin eleva-
tion have been tried but have side effects of their own.
Bromocriptine, a dopamine agonist has been investigated
in several studies for its potential to decrease prolactin
levels. Yuan et al. [105] studied the effects of bromocrip-
tine (5 mg) compared to an herbal preparation, Peony-
Glycyrrhiza Decoction (PGD) in 20 women with elevated
and symptomatic hyperprolactinemia. In both groups, pro-
lactin levels were reduced in about one quarter of subjects;
however, of those with improvements in prolactin, more
PGD subjects had a resolution of prolactin side effects (56%
vs. 21-38%). Another group studied the effect of bromo-
criptine compared to placebo for drug induced hyper-
prolactinemia in an 8 week randomized single blind study.
Six of 45 (13%) resumed menstruation on bromocriptine
compared to 1/15 (7%) on placebo. A 2.5 mg dose of
bromocriptine was not effective while 4/15 (27%) treated
with 10 mg/day regained their menstrual period [106].
However, dopamine agonists such as bromocriptine have
also been associated with worsening of psychosis [107].
In an open label study testing the effectiveness of
cabergoline, an ergot derivative and full dopamine agon-
ist, to improve prolactin related side effects, 11/19 (58%)
male and female participants with schizophrenia had im-
provement in their symptoms [108]. However, cardiopul-
monary complications are a concern with ergot derived
dopamine agonists [109]. Metformin was recently stud-
ied as an adjunct to antipsychotic treatment in a ran-
domized double blind placebo controlled trial. Sixty
seven percent of those assigned to metformin resumed
their menstruation compared to 5% assigned to placebo
in a six month period [110]. In other studies, selegiline
and cyproheptadine were not effective for sexual dys-
function and one small double blind trial has found ben-
efits with sildenafil for sexual dysfunction but this was
not focused on prolactin as a culprit [111,112].
As mentioned, our preliminary work has shown that
aripiprazole can significantly improve hyperprolactinemia
and related side effects as an adjunct to haloperidol in
people with schizophrenia [94]. We have also found that
aripiprazole added to dopamine raising antipsychotics can
decrease prolactin levels and lead to women regaining their
menstrual periods. This strategy is highly effective at de-
creasing prolactin levels and improving related side effects.There are a few case reports with aripiprazole improv-
ing hyperprolactinemia in patients as compared to their
previous treatments [113-115]. Aripiprazole monother-
apy [116-118] in double blind trials has shown improve-
ment in prolactin levels compared to baseline. Kane
et al. [119] completed a large multicenter 16 double
blind placebo controlled study of aripiprazole (2–15 mg/
day) in addition to a stable regiment of quetiapine or ris-
peridone. While there were no statistically significant de-
creases in clinical psychiatric symptoms, aripiprazole
was found to improve prolactin elevations (in both men
and women), with the authors suggesting this deserves
further study as a treatment. In a published study by our
group in both men and women we found that adjunct
aripiprazole therapy with haloperidol significantly de-
creased prolactin in the majority of patients relative to
placebo [94]. Figure 1 below demonstrates the significant
effect of adjunct aripiprazole in patients with schizo-
phrenia having elevated prolactin at baseline (N = 56).
We also have pilot data to suggest that up to 15 mg of
aripiprazole can resolve elevated prolactin in women
with amenorrhea. Twenty-one of 24 (88%) of women in
an open label study of adjunct aripiprazole experienced
resolution of their menstrual periods by 8–16 weeks, as
well as significant decreasing (from 96.6 ng/ml to
28.1 ng/ml means) their prolactin levels [120]. Yasui-
Furukori [121] et al. also found significant improvements
in prolactin and symptoms with 4 weeks of adjunct
aripiprazole (3,6,9 and 12 mg) with the most robust im-
provements seen at the 9 and 12 mg/day dose.
In addition to the prolactin improvements with ad-
junct aripiprazole, there is also data to suggest that
aripiprazole augmentation to existing antipsychotics may
help improve residual psychiatric symptoms (positive,
negative, depressive symptoms). Aripiprazole as an ad-
junctive treatment has been most studied in combination
with clozapine treatment in schizophrenia [122-130]. Ad-
junct aripiprazole has also been shown in double blind
trials to reduce metabolic side effects of olanzapine
[131,132] and clozapine [132].
In a review of 31 studies of strategies to treat hyper-
prolactinemia, Nunes et al. [111] found that only ari-
piprazole appears to have efficacy. Thus, most data
suggests that aripriprazole10-30 mg/day is effective at de-
creasing prolactin, improving prolactin related side effects
and possibly improving residual psychiatric symptoms.
The 15 mg/day dose, lowest of the recommended range,
appears to offer the greatest tolerability while providing
efficacy.
It is important to note that in addition to pharmacologic
treatment strategies such as low dose aripiprazole, patients
should be made aware of these potential prolactin-related
side effects and periodic checks should be made to moni-
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Figure 1 Change in Prolactin Levels over 8 weeks in a Double Blind Trial: Aripiprazole vs. Placebo.
Kelly et al. BMC Psychiatry 2013, 13:214 Page 7 of 14
http://www.biomedcentral.com/1471-244X/13/214clinicians in the field have published recently on the im-
portance of recognition and treatment and that we can




The primary study aim of this recently started IRB ap-
proved study is to determine if adjunct aripiprazole will
resolve or improve prolactin related hormonal side ef-
fects (amenorrhea, oligomenorrhea, galactorrhea). We
hypothesize as our primary outcome that adjunct
aripiprazole will resolve hormonal effects in women
with schizophrenia or schizoaffective disorder and sym-
ptomatic hyperprolactinemia stabilized on risperidone,
paliperidone, or FGAs. Additionally, we have four second-
ary aims. First, to test whether adjunctive aripiprazole will
improve psychiatric symptoms (depression/anxiety, nega-
tive symptoms, positive symptoms), perceived quality of
life, sexual functioning and perceived wellness. We hy-
pothesize that aripiprazole will improve psychiatric symp-
toms, quality of life, sexual functioning and perceived
wellness relative to placebo in women stabilized on risper-
idone, paliperidone, or FGAs. Second, to identify if adjunct
aripiprazole will improve bone turnover as measured by
assays of osteoblastic and osteoclastic activity. We hy-
pothesize that osteoblastic activity will be greater and
osteoclastic activity will be less in women treated with ad-
junct aripiprazole relative to placebo in women stabilized
on risperidone, paliperidone, or FGAs. Third, to examine
side effects of adjunct aripiprazole vs. placebo. We hy-
pothesize that side effect rates will be similar in the two
groups, with the exception of improved metabolic (weight,
lipids, glucose) and prolactin-related side effects on ad-
junct aripiprazole. Our fourth and final secondary aim is
to evaluate the mediator effects of estrogen, progesterone
and prolactin on quality of life, bone turnover and sexual
functioning. In exploratory analyses, we will examine the
relationship of sex hormone changes to various outcomes.Sex hormone levels may predict improvement and serve
as a biomarker for predicting outcome or bone turnover
and determining optimal aripiprazole dose for individual
patients. For example, women who have return of menses
but do not ovulate, as evidenced by lack of luteal proges-
terone surge, may have less improvement in bone turn-
over and sexual side effects.
Overview
Our ongoing study is a 16-week, double blind, placebo con-
trolled randomized trial of aripiprazole (N = 25) or placebo
(N = 25) added to an existing stabilized regimen of prolactin
elevating antipsychotics (risperidone, paliperidone, halo-
peridol, fluphenazine, perphenazine, loxapine). Subjects are
seen every two weeks during the study. At baseline all pa-
tients receive a full medical and psychiatric evaluation to
ensure there are no medical concerns. All subjects must
sign informed consent and pass a quiz, the Evaluation of
Signed Consent (ESC).
Inclusion and exclusion criteria
Inclusion criteria
1. Subjects will be females of any race, with an age
range of 18-50.
2. Subjects will meet DSM-IV TR [135] criteria for
either schizophrenia or schizoaffective disorder. A
best estimate diagnostic approach will be utilized in
which information from the Structured Clinical
Interview for DSM-IV [136] is supplemented by
information from family informants, previous
psychiatrists, and medical records to generate
a diagnosis.
3. Women will need to be taking a stable dose of
antipsychotic regimen for at least two months and
are considered to have stable symptoms by the
treating psychiatrist. This regimen must include any
form of risperidone or paliperidone , or first
generation antipsychotics (i.e., haloperidol,
perphenazine, loxapine, or fluphenazine),
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(either identified at screening or from the past
6 weeks in the medical record).
5. All women will have evidence of a prolactin related
hormonal side effect (amenorrhea, oligomenorrhea
or galactorrhea) or significant sexual dysfunction.
This will be determined by patient report/history
and medical record/clinician interview.
Oligomenorrhea is defined as infrequent,
irregularly timed episodic bleeding occurring at
intervals of more than 35 days from the previous
menstrual cycle and amenorrhea is defined as
absence of menstruation for three menstrual cycles
or 6 months [137]. Galactorrhea is defined as
lactation or copious milk secretion.
6. Subjects must be judged competent to participate in
the informed consent process and provide voluntary
informed consent, by scoring a 10 out of 12 on the
Evaluation to Sign Consent (ESC).Exclusion criteria
1. Postmenopausal women will be excluded. Since it
may be difficult to determine menopause in patients
with amenorrhea, any women more than 45 years
will be assessed for menopausal symptoms, including
but not limited to: hot flushes, depression,
excitability and fatigue. A medical doctor will advise
on the menopausal status.
2. Patients with a history of a pituitary tumor
(microadenoma, macroadenoma, neoplasm) will not
be included in the study. Previous medical records
will be obtained if possible to examine prolactin
levels and medical histories.
3. Subjects with documented Cushing’s disease, or who
are pregnant or currently lactating post pregnancy
will be excluded.
4. Subjects who meet DSM-IV TR criteria for alcohol
or substance abuse within the last month are
excluded. Subjects with nicotine use or dependence
will not be excluded.
5. Medications which may affect prolactin or cause
sexual dysfunction, including: metoclopramide,
methyldopa, reserpine, amoxapine, droperidol,
prochlorperazine, promethazine, bromocriptine,
and cabergoline.
There are many medications that may affect sexual
function (not hormonal side effects) unrelated to dopa-
mine transmission. These are only permitted as long as
the subject has been receiving them for greater than
4 weeks (SSRIs, mood stabilizers, diuretics, antihyperten-
sives, H2antagonists, buproprion). We allow these medi-
cations to enhance generalizability.Study assessments
Table 1 outlines assessments performed throughout the
study. In addition, a more detailed description of these
assessments has been included in the text below.
Hormonal side effects
A menstrual diary is used to measure hormonal side ef-
fects, specifically her menstrual period and galactorrhea.
Each woman is given a Menstrual Diary and is instructed
to note any day that they experience bleeding or pain
throughout the study. Study staff review the diary with
participants every 2 weeks to ensure that the diary is being
correctly used and to determine occurrence of menstrual
bleed. This diary is a monthly calendar that asks subjects
to include any day with menstrual flow (Spotting = 1,
Light = 2, Moderate = 3, Heavy = 4). If a subject has galac-
torrhea at baseline, she is asked to note the presence of
lactation daily in the diary. Participants bring the diary to
biweekly assessments and are reminded to complete the
diary by twice weekly phone calls. If the diary is not filled
out, the subject is shown a calendar and asked to recall
any menstrual bleeding in the last two weeks and weekly
reminders are provided to the subject until the next visit.
Regaining regular menstruation is defined as: menstrual
bleeding for 3–8 days followed by another period of men-
strual bleeding for 3–8 days that occurs 21–35 days after
the first episode. This is the justification for the 16-week
trial length. Based on pilot data the menstrual period
should return within 8–12 weeks and 16 weeks should
provide adequate time to see two regular menstrual pe-
riods return. Resolution of galactorrhea is defined as the
absence of any lactation or milk discharge for a period
of ≥ 7 days. Breast exams are done every two weeks during
the study until lactation is no longer present.
Sexual function assessments
Sexual function is evaluated using the Female Sexual Func-
tion Index (FSFI) [138] as the primary rating scale and the
Arizona Sexual Experience Scale (ASEX) [139] and Female
Sexual Distress Scale-Revised (FSDS-R) [140] as secondary
measures. The FSFI is a brief (19-item) multidimensional
scale that has been found reliable and valid for assessing
sexual function in women. It has been used in women with
schizophrenia and does not require subjects to have a
regular sexual partner. Weigel et al. [138] found a FSFI cut
point > 26.55 optimal for identifying presence of sexual
dysfunction using receiver operating curves. The FSDS-R
is a scale of 13 items rated 0–4 and has been found to be
valid and reliable. A cutoff score >15 is used to determine
presence of sexually related personal distress. The ASEX
has five items rated from 1 (enhanced) to 6 (markedly im-
paired), with ASEX total scores ranging from 5–30. This
scale has been demonstrated to be valid and reliable in
people with schizophrenia or schizoaffective disorder. A
Table 1 Schedule of events for study procedures
Week of treatment Baseline 1 2 4 6 8 10 12 14 16
Physical exam, EKG, demographic information and forms X
Childhood Experience of Care and Abuse Questionnaire (CECA.Q), and Ways of Coping Checklist (WCC) X
Drug Use Information X X X X X X X X X X
Tobacco Craving Questionnaire, smoking questionnaire, Nicotine Dependency Form and CO (smokers
only, 30 minutes post cig)
X X X
Fertility and Sexual Behavior Questionnaire , menstrual attitude scale X X
Urine pregnancy test X X X X X X X X X X
Vital signs, blood pressure, weight, waist circumference X X X X X X X X X X
Prolactin X X X X X X X X X X
Estradiol, progesterone* X X X X X X X X X X
Salivary cortisol X X X
Risperidone and 9-OHrisperidone plasma levels, thyroid panel including TRH X X X
CBC, Chemistry and full lipid panel (Total cholesterol, triyglycerides, HDL, LDL, VLDL), FBG, HbA1C X X X
Highly sensitivity C- reactive protein (CRP) X X X
Osteocalcin, bone specific alkaline phosphatase, urinary NTx and serum CTx X X X X
Cytokines X X X
Parathyroid hormone, homocysteine, and 25-hydroxyvitamin D levels X X X
Medication accountability and pill count X X X X X X X X X
BPRS, SANS, CDS. CGI X X X X X X X X X X
RBANS X X
SAS, BAS, SEC X X X X X X X X X X
AIMS X X
SF-36, DAI, FSFI, FSDS-R, ASEX, PGWB X X X X X
Menstrual diary** (kept daily) checked X X X X X X X X X X
Breast examination*** X X X X X X X X X
Exit Interview, Perceived Study Benefits X
*Subjects will be given a salivary test at each visit and will be asked to perform one for the next week, refrigerate and return.
**Phone calls will be made twice weekly to remind the subjects to keep their menstrual diary daily.
***Done by female research staff or nurse (will only be repeated if galactorrhea is noted during baseline).
Kelly et al. BMC Psychiatry 2013, 13:214 Page 9 of 14
http://www.biomedcentral.com/1471-244X/13/214total score of > 19 is indicative of sexual dysfunction. All
raters for the FSFI, ASEX and FSDS-R are women to
avoid any embarrassment or lack of detail in responses
to male raters.
Psychiatric symptom assessments
The following instruments are used to assess neuropsychi-
atric symptoms: Brief Psychiatric Rating Scale (BPRS)
[141]; Scale for the Assessment of Negative Symptoms
(SANS) [142]; Calgary Depression Scale (CDS) [143]; Clin-
ical Global Impression Scale (CGI) [144] and the Repeat-
able Battery for the Assessment of Neuropsychological
Status (RBANS) [145]. The BPRS four positive symptom
items - conceptual disorganization, suspiciousness, hallu-
cinatory behavior, and unusual thought content - are used
to measure positive psychotic symptoms. The SANS total
score, minus the global items, inappropriate affect, poverty
of content of speech, and attention items, is used to meas-
ure negative symptoms. The inappropriate affect, povertyof content of speech, and attention items are excluded as
lacking construct validity and because factor analytic study
results suggest that these items are not closely related to
negative symptoms [146]. The CDS total score is used to
measure depressive symptoms and CGI severity of illness
item is used to assess global changes. The CDS is a 9-item
scale designed specifically to assess depressive symptoms
in patients with schizophrenia. The CDS has been shown
to be reliable and have good construct validity. Lastly, the
RBANS is a brief neurocognitive battery with four alter-
nate forms, measuring immediate and delayed memory,
attention, language, and visuospatial skills.
Subject wellness, quality of life and satisfaction
with treatment
The SF-36 Health Survey (SF-36) [147]; Drug Attitude
Inventory (DAI) [148]; and the Psychological General
Well Being Schedule (PGWB) [149] are used. The SF-36
is a 36-item scale used to indicate general health status.
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ioral functioning, perceived well-being, social and role dis-
ability and personal evaluations of health in general. It is
found to be valid and reliable. The DAI is a 30-item scale
that focuses on the subjective effect of antipsychotic medi-
cations in people with schizophrenia. Subjective responses
are scored on a euphoric-dysphoric continuum, with scores
ranging from −44 to 44. This scale has good reliability and
validity. The PGWB is a 22-item scale for measuring qual-
ity of life in people with schizophrenia. It focuses on the
inner personal state rather than external conditions such
as income, work or home environment. It has 6 subscales:
anxiety, depressed mood, positive well-being, self-control,
general health, and vitality. Adherence to medication is
assessed by pill count. An exit interview asks women if
they received benefits and if they would like to continue
treatment. The rater conducting the interview is different
from anyone responsible for outcome ratings and is also
blind to treatment assignment.
Side effect measures
The Simpson-Angus Extrapyramidal Symptom Rating
Scale (SAS) [150], Barnes Akathisia Scale (BAS) [151],
Abnormal Involuntary Movement Scale (AIMS) and Side
Effect Checklist (SEC) are used to assess side effects
throughout the study.
Laboratory assessments
Laboratory measurements are obtained including serum
prolactin, cytokines, C reactive protein, lipids, fasting
glucose and thyroid hormone. Estradiol, and progester-
one are measured weekly by collection of a saliva sam-
ple, permitting more accurate assessment of estrogen
exposure and ovulation and a less invasive or burden-
some measure compared to serum or urine. Measures
of bone turnover include measures of osteoblastic activ-
ity (plasma osteocalcin and bone specific alkaline phos-
phatase) and measures of osteoclastic activity (urinary
N-telopeptide of type I collagen crosslinks (NTx) and
C-telopeptide of collagen crosslinks (CTx)). Parathyroid
hormone, homocysteine, and 25-hydroxy-vitamin D
levels are measured at baseline, week 8 and week 16.
High bone turnover is reported in schizophrenia but
changes over time have not been well characterized. El-
evated homocysteine levels have recently been reported
to contribute to decreased bone turnover in schizophre-
nia. Increased osteoblastic activity indicates an increase
in bone formation and increased osteoclastic activity is
a measure of bone reabsorption. Normalization of pro-
lactin levels is defined as a prolactin level < 24 ng/ml.
All fasting laboratory measurements are drawn in the
morning of testing prior to breakfast. Some subjects
may meet eligibility criteria due to the presence of ga-
lactorrhea, but still have regular menses. To controleffects of menstrual cycles on prolactin levels, menstruat-
ing subjects have randomized treatment started on the 7th
day after starting their menstrual period. Cytokines are
measured by Luminex Technology at the University of
Maryland Core Cytokine Laboratory. The following are
measured: TNF-alpha, IL-2, IL-6, IL-12, adiponectin, lep-
tin, IFN gamma, all known to be stimulated by elevated
prolactin.
Study medication
The intervention starts at a dose of 5 mg/day of
aripiprazole or matching placebo tablet and is escalated to
10 mg PO daily at the end of week 2 and further increased
to 15 mg/day at the end of week 8 in women who have not
yet achieved a first menstrual period. If a woman regains
her menstrual period during titration, she remains on the
lowest dose at which menses occurred. With this escalation
plan, all women in the pilot study had first menses by
12 weeks, giving a high probability of observing two nor-
mal menstrual periods by 16 weeks. Dosing of aripiprazole
or placebo may be also be modified to 5 mg/day by the
clinician if side effects occur. Participants are randomized
by the study statistician and treatment assignments given
only to the unblinded research pharmacist. A permuted
block randomization sequence is used; the randomization
will be stratified by inpatient/outpatient status. During the
study subjects will be maintained on the current dose of
antipsychotics and antipsychotics will be dispensed utiliz-
ing the same pharmacy procedures as the double blind
medication. Study physicians are instructed to avoid
changing the dose of antipsychotic medication through-
out the study, however this is permissible. Subjects will
be able to receive anticholinergic medications as needed
(e.g., benztropine and diphenhydramine) for extrapyr-
amidal side effects, propranolol for akathisia, and ben-
zodiazepines (e.g., lorazepam) for agitation or anxiety.
Data analysis
All analyses will be conducted on an intention to treat
basis, according to randomly assigned treatment, and will
adjust for inpatient/outpatient status and baseline prolac-
tin levels. The primary outcome of this study is the reso-
lution of amenorrhea, oligomenorrhea, or galactorrhea,
which will be analyzed at two-sided alpha = 0.05. We will
compare the percentages in whom hormonal side effects
have remitted (normal 3–8 day menstrual period followed
by another normal 3–8 day menstrual period 21–35 days
apart or resolution of galactorrhea) by end of study (week
16) in the aripiprazole versus placebo groups using a
Mantel-Haenszel chi-square test at two-sided alpha = 0.05
to summarize evidence across strata defined by inpatient/
outpatient status and by baseline prolactin (25–75 ng/ml
and >75 ng/ml. This outcome will be potentially missing
in women who withdraw before Week 16, or in women
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Weeks 12 and 16. We will assume that women who with-
draw from treatment early will not achieve sustained re-
mission of hormonal side effects. From data for women in
the study, whose first normal menstrual period is before
Week 12, we may estimate the probability, pm that a first
normal menstrual period is followed by a second normal
menstrual period 21–35 days later. Then if women in each
stratum have first menstrual period after Week 12, the
probability that k of them have second normal menstrual
period after Week 16 is given by the binomial distribution
p(k) =m!/k!(m-k)! × pm
k (1-pm )
m-k. For all possible out-
comes for the limited number of missing cases, we may
evaluate the p-value, pmh, of the Mantel-Haenszel chi-
square test and the probability p(k), of obtaining that p-
value. From this we may obtain the expected p-value,
given by Σk p(k) pmh(k), together with 95% confidence
limits on the likelihood, given the missing data pattern, of
getting that p-value. These will let us see the sensitivity of
our study conclusions to our assumptions about women
with late first menstrual periods. Sexual functioning, gen-
eral wellbeing, psychiatric symptoms, and bone turnover
will be assessed using mixed models repeated measures
analysis of covariance of the form: follow-up measure-
ment = baseline measurement + treatment + week + treat-
ment x week, where within-subject correlation of repeated
measurements is assessed with an unstructured covariance
model and “week” is not treated as a continuous measure
but a set of categorical indicators of the week at which a
measurement is collected. With this model, the “treat-
ment” term estimates the average (across weeks) differ-
ence between treatments and the treatment x week term
assesses whether this difference varies over time.
Power for the primary outcome
We based power calculations on our preliminary data on
remission of menstrual abnormalities. Shim et al. [94]
found that among females who were treated with haloperi-
dol and who had menstrual abnormalities (amenorrhea or
oligomenorrhea) at baseline, 63% regained normal men-
struation among those assigned to adjunctive aripiprazole
and 0% for those assigned to placebo. If we assume 20%
dropout by Week 16, with dropouts imputed to remain ab-
normal, and we assume 63% remission in completers [94],
we would get 50% remission in the total sample. Based on
the pilot study, we might assume a higher rate of remission
with longer follow-up than seen in the 8-week study by
Shim et al. Using two-sided chi-square tests at alpha = 0.05,
if we assume 10% remission in women assigned to placebo,
and 63% remission in completers, we would have power =
0.89 to detect this difference at with n = 25 per group; if we
assume 70% remission in completers (56% in the total sam-
ple randomized), we would have power = 0.95 to detect this
difference with n = 25 per group.Regulatory
The study has been fully IRB approved, registered in clin-
ical trials.gov and is reviewed by a Data Safety Monitoring
Board. Participants are compensated for their time.
Discussion
Hyperprolactinemia is a common occurrence with many
antipsychotics and is very often associated with distressing
side effects and symptoms, particularly in women. The
consequences of prolactin elevations can be profound in-
cluding negative health outcomes, nonadherence and, as
recently identified, suicide. We have presented details on a
currently ongoing clinical trial, the DAAMSEL study, to
increase recognition of prolactin-related adverse effects
and treatment research around this critical issue.
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